Study of Valemetostat Tosylate as a Single Agent in Patients With Relapse/Refractory B-cell Lymphoma

Lymphoma, B-Cell Clinical Trial

Official title:

A Phase II Open-label Study Evaluating Valemetostat Tosylate as a Single Agent in Patients With Relapse/Refractory B-cell Lymphoma

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT04842877
• Other study ID #: VALYM
• Status: Active, not recruiting
• Phase: Phase 2
• Start date: June 11, 2021
• Est. completion date: October 2024

Study information

• Verified date: March 2024
• Source: The Lymphoma Academic Research Organisation
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a multicenter, prospective, single arm, non-randomized, open-label, phase 2 clinical study to evaluate safety and efficacy of valemetostat tosylate (DS-3201b) in patients with relapsed or refractory B cell lymphoma with 6 cohorts of patients including 2 biology-driven cohorts. Up to 141 patients will be enrolled in 6 different cohorts (40 patients with aggressive B-cell lymphoma, 41 with follicular lymphoma (FL), 20 with Mantle Cell Lymphoma (MCL) and 20 with other indolent lymphomas, and 20 patients with Hodgkin lymphoma (HL)). FL patients with EZH2 mutant (gain of function mutations) will be enrolled in the cohort 2bis. At least 8 aggressive B-cell lymphoma patients with EZH2 mutant will be enrolled in the cohort 1. The primary endpoint is the overall response rate (ORR) determined by investigator assessment.

Description:

Each cycle consists of 28 days. Valemetostat tosylate (DS-3201b) is given continuously at 200 mg once daily (QD). The total duration is expected to be approximately 3 years, assuming an expected enrollment duration of 2 years and a minimum duration of valemetostat tosylate (DS- 3201b) administration of 12 cycles of 28 days for the last enrolled patient.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 141
• Est. completion date: October 2024
• Est. primary completion date: October 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1 - Participants with confirmed histological diagnosis of B-cell non-Hodgkin's lymphoma of aggressive B-cell lymphoma (diffuse large B-cell lymphoma-not otherwise specified, primary mediastinal B-cell lymphoma, high grade B-cell lymphoma-not otherwise specified and high grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangement, transformed indolent lymphoma and grade 3b follicular lymphoma), FL (grade 1, 2, 3a), MCL, MZL or other indolent lymphoma (Waldenström macroglobulinemia), or HL according to the World Health Organization (WHO) 2016 classification of hematopoietic and lymphoid tissue.

2. Participant who had progressive disease (PD) or did not have a response (CR or PR) in previous systemic therapy, or relapsed or progressed after previous systemic therapy 3. Participant who has measurable disease by the Lugano criteria (ie longest diameter of a nodal site > 1.5cm and/or longest diameter of an extranodal site > 1.0 cm) 4. Participant who had previous standard therapy with at least: (note: patients having received prior

CAR-T therapy can be enrolled):

1. For aggressive B-cell lymphoma : 1 prior line of therapy (in transformed indolent lymphoma patient must have received at least one line of treatment containing an anthracycline-based regimen before of after transformation) containing an anti-CD20 antibody and an anthracycline (unless anthracycline-based therapy is contraindicated) and if patient is considered unable to benefit from intensification treatment with autologous stem cell transplant (ASCT) as defined by at least one of the following

criteria:

• Relapsed following, or refractory to, previous ASCT
• Ineligible for intensification treatment due to age or significant comorbidity
• Ineligible for intensification treatment due to failure to mobilize an acceptable number of hematopoietic stem cells
• Refused intensification treatment and/or ASCT

2. For FL, MZL and other indolent non-Hodgkin's lymphoma (NHL): 2 prior lines of systemic therapy with at least one anti-CD20 monoclonal antibody. Local involved field radiotherapy for limited stage disease is not considered as a previous line. Subjects with prior ASCT may be included. Note: for Splenic Marginal Zone Lymphoma (SMZL), splenectomy is considered as one line; for Extranodal Marginal Zone Lymphoma (ENMZL), Helicobacter pylori eradication is not considered as a previous line.

3. For MCL: 2 prior lines including at least one immunochemotherapy and one BTK inhibitor.

4. For HL: 3 prior lines including at least one line with anthracycline-based chemotherapy (unless anthracycline-based therapy is contraindicated), one line containing brentuximab-vedotin and one line containing an anti-PD1 or anti-PDL1 antibody and must be considered unable to benefit from intensification treatment with autologous stem cell transplant (ASCT) as defined by at least one of the following

criteria:

• Relapsed following, or refractory to, previous ASCT
• Did not achieve at least a partial response to a standard salvage regimen
• Ineligible for intensification treatment due to age or significant comorbidity
• Ineligible for intensification treatment due to failure to mobilize an acceptable number of hematopoietic stem cells
• Refused intensification treatment and/or ASCT 5. Participant with Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2 6. Adequate renal function defined as calculated creatinine clearance = 40 mL/min per the Cockcroft

and Gault formula 7. Adequate bone marrow function:

• Absolute neutrophil count (ANC) > 1000/mm3 (= 1 × 109/L) without growth factor support (G-CSF) for at least 7 days
• Platelets = 75,000/mm3 (= 75 × 109/L) evaluated after at least 7 days since last platelet transfusion
• Hemoglobin > 8.0 g/dL evaluated after at least 7 days since last transfusion 8.

Adequate liver function:

• Total bilirubin < 1.5 × the upper limit of normal (ULN) except for unconjugated hyperbilirubinemia due to Gilbert's syndrome
• Alkaline phosphatase (ALP) (in the absence of bone disease), alanine aminotransferase (ALT), and aspartate aminotransferase (AST) < 3 × ULN (< 5 × ULN if subject has liver involvement due to lymphoma) 9. Adequate tissue (surgical excision is recommended) for central pathology review and biological characterisation 10. Patient being successfully tested for EZH2 mutation status at study specific laboratories (for cohort 1, 2 and 2bis) 11. Subjects with a history of hepatitis B or C are eligible on the condition that subjects have adequate liver function and are hepatitis B surface antigen negative and have undetectable serum hepatitis B virus (HBV) DNA and hepatitis C virus (HCV) RNA, respectively.

12. Females of childbearing potential must agree to use an highly effective birth control methods (defined in §13.6.1) during the following time periods related to this study: 1) for at least 28 days before starting study drug; 2) while participating in the study; 3) dose interruptions; and 4) for at least 3 months after discontinuation of study treatment 13. Males with partners of childbearing potential must agree to use highly effective birth control methods during the study and 3 months after last treatment administration 14. Male and female participant =18 years of age at the time of informed consent 15. Patient covered by any social security system (France) 16. Patient who understands and speaks one of the country official language 17. Participant who has provided written consent to participate in the study

Exclusion Criteria:

1. Participant with prior exposure to EZH2 inhibitor

2. Participant with active lymphomatous involvement of the central nervous system (CNS) at screening

3. Any prior treatment-related (ie, chemotherapy, immunotherapy, radiotherapy), clinically significant toxicities have not resolved to = Grade 1 per CTCAE version 5.0, or prior treatment-related toxicities are clinically unstable and clinically significant at time of enrollment.

4. Major surgery within 4 weeks before the first dose of study drug.

5. Inability to take oral medication, or malabsorption syndrome or any other uncontrolled gastrointestinal condition (eg, nausea, diarrhea, or vomiting) that might impair the bioavailability of the drug

6. Subjects currently taking medications that are known moderate or strong CYP3A inducers

• If currently used, these medications need to be discontinued at least 14 days prior to study drug administration; replacement by alternative medications that are not moderate or strong CYP3A inducers can be considered according to medical need

7. Vaccinated with live, attenuated vaccines within 6 months of enrollment (except COVID vaccine)

8. Use of any standard or experimental anti-cancer drug therapy within 4 weeks or a minimum of 3 half lives of the drug, whatever the shortest prior to first administration of study drug,

9. History of CAR T-cells therapy within 30 days prior to the first dose of study drug

10. History of autologous or allogeneic hematopoietic cell transplantation (HCT) within 90 days prior to the first dose of study drug

11. Patients taking corticosteroids within 2 weeks prior to first administration of study drug, unless administered at a cumulated dose equivalent of prednisone to = 10mg /day (within these 2 weeks).

12. Participant with significant cardiovascular impairment: history of congestive heart failure greater than New York Heart Association (NYHA) Class II, uncontrolled arterial hypertension, unstable angina, myocardial infarction, or stroke within 6 months of the first dose of study drug; or cardiac ventricular arrhythmia

13. Subjects with malignancies other than B cell lymphomas except subjects who have been disease-free for 2 years (subjects with a history of a completely resected non-melanoma skin cancer or successfully treated in situ carcinoma are eligible).

14. Positive serology of human immunodeficiency virus (HIV)

15. Participant with prolongation of corrected QT interval using Fridericia's formula (QTcF) to > 470 milliseconds (msec) (obtained on average of 3 ECGs)

16. Participant with venous thrombosis or pulmonary embolism not treated

17. Participant with complications of hepatic cirrhosis, interstitial pneumonia, or pulmonary fibrosis

18. Participant with active infection requiring systemic therapy

19. Woman who are pregnant (positive serum pregnancy test at screening) or breastfeeding

20. Participant who were deemed as inappropriate to participate in the study by the investigator or coinvestigator

Related Conditions & MeSH terms

• Lymphoma
• Lymphoma, B-Cell
• Recurrence

Intervention

Drug:
• Valemetostat tosylate
200mg QD continuously until disease progression, consent withdrawal, unacceptable drug-related toxicity, lost to follow-up, major protocol deviation, pregnancy, termination by sponsor or death, whichever occurs first.

Locations

Country	Name	City	State
Belgium	A.Z. Sint Jan AV	Bruges
Belgium	University Hospital Gent	Gent
Belgium	CH Tourelle Peltzer	Verviers
Belgium	CHU Mont-Godinne	Yvoir
France	CH d'Avignon	Avignon
France	CH de la Côte Basque	Bayonne
France	Institut Bergonié	Bordeaux
France	Institut d'Hématologie de Basse Normandie	Caen
France	Ch Metropole Savoie - Site Chambery	Chambéry
France	CHU d'Estaing	Clermont-Ferrand
France	François Lemonnier	Créteil
France	CHU de Dijon	Dijon
France	Chd de Vendee	La Roche-sur-Yon
France	Clinique Victor Hugo	Le Mans
France	Service des Maladies du Sang - CHRU de Lille	Lille
France	Institut Paoli Calmette	Marseille
France	CHU de Montpellier	Montpellier
France	Gh Region Mulhouse Et Sud Alsace	Mulhouse
France	CHU Hôtel Dieu	Nantes
France	Emmanuel Bachy	Pierre Bénite
France	CHU Pontchaillou	Rennes
France	Ch de Bretagne Atlantique -	Vannes

Sponsors (2)

Lead Sponsor	Collaborator
The Lymphoma Academic Research Organisation	Daiichi Sankyo

Countries where clinical trial is conducted

Belgium,  France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Overall Response Rate (ORR)	ORR according to Lugano Response Criteria (2014)	when mature response rate data have been observed, estimated as no later than 12 months after the last patient in each cohort has received the first dose of study drug
Secondary	Complete Response Rate (CRR)	CRR according to Lugano response Criteria	After 3 cycles of treatment (each cycle of 28 days, id est (ie) 3 months)
Secondary	Complete Response (CR) Rate	CRR according to Lugano response Criteria	After 6 cycles of treatment (each cycle of 28 days, id est (ie) 6 months)
Secondary	Complete Response (CR) Rate	CRR according to Lugano response Criteria	After 9 cycles of treatment (each cycle of 28 days, id est (ie) 9 months)
Secondary	Complete Response (CR) Rate	CRR according to Lugano response Criteria	After 12 cycles of treatment (each cycle of 28 days, id est (ie) 12 months)
Secondary	Progression-Free Survival (PFS)	PFS is defined as the time from inclusion into the study to the first observation of documented clinical disease progression or death due to any cause.	After 12 cycles(each cycle is 28 days) of study treatment for the last patient included (estimated 3 years of study)
Secondary	Duration of response (DoR)	The DoR is defined as the time from attainment of CR or PR based on Lugano Response Criteria 2014 to the date of first documented disease progression, relapse (local assessment) or death from any cause	After 12 cycles (each cycle is 28 days) of study treatment for the last patient included (estimated 3 years of study)
Secondary	Time to Response (TTR)	The TTR is defined defined as the time from the first dose date to the date of attainment of CR or PR based on Lugano Response Criteria 2014	After 12 cycles (each cycle is 28 days) of study treatment for the last patient included (estimated 3 years of study)
Secondary	Number of Serious Adverse Events (SAE)	The frequency of SAE	After 12 cycles of study treatment (each cycle is 28 days) for the last patient included (estimated 3 years of study)
Secondary	Pharmacokinetics: quantity of valemetostat tosylate (DS-3201b) and major metabolite (CALZ-1809a)	quantity of valemetostat tosylate (DS-3201b) and major metabolite (CALZ-1809a)	predose
Secondary	Pharmacokinetics: quantity of valemetostat tosylate (DS-3201b) and major metabolite (CALZ-1809a)	quantity of valemetostat tosylate (DS-3201b) and major metabolite (CALZ-1809a)	1 hour post-dose at Cycle1 Day 1
Secondary	Pharmacokinetics: quantity of valemetostat tosylate (DS-3201b) and major metabolite (CALZ-1809a)	quantity of valemetostat tosylate (DS-3201b) and major metabolite (CALZ-1809a)	2 hours post-dose at Cycle1 Day 1
Secondary	Pharmacokinetics: quantity of valemetostat tosylate (DS-3201b) and major metabolite (CALZ-1809a)	quantity of valemetostat tosylate (DS-3201b) and major metabolite (CALZ-1809a)	4 hours post-dose at Cycle1 Day 1
Secondary	Pharmacokinetics: quantity of valemetostat tosylate (DS-3201b) and major metabolite (CALZ-1809a)	quantity of valemetostat tosylate (DS-3201b) and major metabolite (CALZ-1809a)	5 hours post-dose at Cycle1 Day 1
Secondary	Pharmacokinetics: quantity of valemetostat tosylate (DS-3201b) and major metabolite (CALZ-1809a)	quantity of valemetostat tosylate (DS-3201b) and major metabolite (CALZ-1809a)	predose at Cycle1 Day 8
Secondary	Pharmacokinetics: quantity of valemetostat tosylate (DS-3201b) and major metabolite (CALZ-1809a)	quantity of valemetostat tosylate (DS-3201b) and major metabolite (CALZ-1809a)	predose at Cycle1 Day 15
Secondary	Pharmacokinetics: quantity of valemetostat tosylate (DS-3201b) and major metabolite (CALZ-1809a)	quantity of valemetostat tosylate (DS-3201b) and major metabolite (CALZ-1809a)	predose at Cycle1 Day 22